INDV Graph | Indivior Pharmaceuticals, Inc.

INDV Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $343.00M; Cost of revenue $50.00M; Selling, general and administrative $122.00M; Operating expenses $134.00M.
2026-03-31: Revenue $317.00M; Cost of revenue $40.00M; Selling, general and administrative $124.00M; Operating expenses $139.00M.
2025-12-31: Revenue $358.00M*; Cost of revenue $67.00M*; Selling, general and administrative $189.00M*; Operating expenses (m).
2025-09-30: Revenue $314.00M; Cost of revenue $83.00M; Selling, general and administrative $155.00M; Operating expenses $187.00M.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Cost of revenue	Selling, general and administrative	Operating expenses	Income tax	Net income
2026-06-30	$343.00M	$50.00M	$122.00M	$134.00M	$38.00M	$122.00M
2026-03-31	$317.00M	$40.00M	$124.00M	$139.00M	$26.00M	$89.00M
2025-12-31	$358.00M*	$67.00M*	$189.00M*	(m)	-$21.00M*	$102.00M*
2025-09-30	$314.00M	$83.00M	$155.00M	$187.00M	-$5.00M	$42.00M
2025-06-30	$302.00M	$52.00M	$158.00M	$179.00M	$44.00M	$18.00M
2025-03-31	$266.00M	$44.00M	$133.00M	$156.00M	$11.00M	$47.00M
2024-12-31	(m)	(m)	$175.00M	$205.00M	$17.00M	$21.00M
2024-09-30	$307.00M	$66.00M	$142.00M	$206.00M	$8.00M	$22.00M
2024-06-30	$299.00M	$79.00M	$152.00M	$338.00M	-$23.00M	-$97.00M
2024-03-31	$284.00M	$38.00M	$143.00M	$171.00M	$11.00M	$61.00M

Revenue and expense 6 month

Period end	Revenue	Cost of revenue	Selling, general and administrative	Operating expenses	Income tax	Net income
2026-06-30	$660.00M	$90.00M	$245.00M	$273.00M	$65.00M	$211.00M
2025-06-30	$568.00M	$96.00M	$291.00M	$334.00M	$56.00M	$65.00M
2024-06-30	$583.00M	$117.00M	$295.00M	(m)	-$12.00M	-$36.00M

Revenue and expense 9 month

Period end	Revenue	Cost of revenue	Selling, general and administrative	Operating expenses	Income tax	Net income
2025-09-30	$881.00M	$179.00M	$445.00M	$521.00M	$50.00M	$108.00M
2024-09-30	$889.00M	$183.00M	$437.00M	$715.00M	-$4.00M	-$14.00M

Revenue and expense 12 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Operating expenses	Income tax	Net income
2025-12-31	$1.24B	$246.00M	(m)	$634.00M	(m)	$29.00M	$210.00M
2024-12-31	$1.19B	$231.00M	(m)	$612.00M	$919.00M	$13.00M	$7.00M
2023-12-31	$1.09B	$174.00M	$106.00M	$565.00M	$1.07B	-$19.00M	-$126.00M
2022-12-31	$901.00M	$151.00M	$72.00M	$466.00M	$827.00M	-$43.00M	-$42.00M
2021-12-31	(m)	(m)	$52.00M	$431.00M	(m)	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Viking Therapeutics, Inc. (VKTX)	United States	$4.287B	-8.51
Tango Therapeutics, Inc. (TNGX)	United States	$4.154B	-42.53
Edgewise Therapeutics, Inc. (EWTX)	United States	$4.470B	-22.23
AbCellera Biologics Inc. (ABCL)		$3.879B	-14.59
ACADIA PHARMACEUTICALS INC (ACAD)	United States	$3.823B	11.45
Xenon Pharmaceuticals Inc. (XENE)		$3.684B	-14.27
Veradermics, Inc (MANE)	United States	$4.839B
Organon & Co. (OGN)	United States	$3.603B	17.03
IDEAYA Biosciences, Inc. (IDYA)	United States	$3.540B	-20.52
Erasca, Inc. (ERAS)	United States	$5.073B	-19.96